Found: 60
Select item for more details and to access through your institution.
Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2020, v. 146, n. 2, p. 503, doi. 10.1007/s00432-019-03078-9
- By:
- Publication type:
- Article
CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: biomarker correlates from the randomized phase-2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer
- Published in:
- Frontiers in Oncology, 2015, p. 1, doi. 10.3389/fonc.2015.00123
- By:
- Publication type:
- Article
Current status and evolution of preclinical drug development models of epithelial ovarian cancer.
- Published in:
- Frontiers in Oncology, 2013, v. 3, p. 1, doi. 10.3389/fonc.2013.00296
- By:
- Publication type:
- Article
Current status and evolution of preclinical drug development models of epithelial ovarian cancer.
- Published in:
- Frontiers in Oncology, 2013, v. 3, p. 1, doi. 10.3389/fonc.2013.00296
- By:
- Publication type:
- Article
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-30568-1
- By:
- Publication type:
- Article
Treatment of Recurrent Platinum-Sensitive Epithelial Ovarian Cancer.
- Published in:
- European Journal of Clinical & Medical Oncology, 2010, v. 2, n. 2, p. 71
- By:
- Publication type:
- Article
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
- Published in:
- Current Oncology Reports, 2016, v. 18, n. 5, p. 1, doi. 10.1007/s11912-016-0515-z
- By:
- Publication type:
- Article
Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Mesenchymal gene program--expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.
- Published in:
- Journal of Clinical Investigation, 2014, v. 124, n. 6, p. 2611, doi. 10.1172/JCI69815
- By:
- Publication type:
- Article
Acupuncture for Chemotherapy-Induced Neutropenia in Patients with Gynecologic Malignancies: A Pilot Randomized, Sham-Controlled Clinical Trial.
- Published in:
- Journal of Alternative & Complementary Medicine, 2009, v. 15, n. 7, p. 745, doi. 10.1089/acm.2008.0589
- By:
- Publication type:
- Article
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-25904-w
- By:
- Publication type:
- Article
Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2021, v. 28, n. 11, p. 6705, doi. 10.1245/s10434-021-09746-w
- By:
- Publication type:
- Article
Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks.
- Published in:
- 2020
- By:
- Publication type:
- journal article
An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
- Published in:
- 2020
- By:
- Publication type:
- journal article
BRAF and AXL oncogenes drive RIPK3 expression loss in cancer.
- Published in:
- PLoS Biology, 2018, v. 16, n. 8, p. 1, doi. 10.1371/journal.pbio.2005756
- By:
- Publication type:
- Article
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.
- Published in:
- International Journal of Clinical Oncology, 2022, v. 27, n. 12, p. 1881, doi. 10.1007/s10147-022-02247-0
- By:
- Publication type:
- Article
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer.
- Published in:
- International Journal of Clinical Oncology, 2010, v. 15, n. 4, p. 390, doi. 10.1007/s10147-010-0073-6
- By:
- Publication type:
- Article
Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations.
- Published in:
- PLoS ONE, 2013, v. 8, n. 11, p. 1, doi. 10.1371/journal.pone.0080023
- By:
- Publication type:
- Article
Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer.
- Published in:
- PLoS ONE, 2012, v. 7, n. 2, p. 1, doi. 10.1371/journal.pone.0030269
- By:
- Publication type:
- Article
High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary.
- Published in:
- PLoS ONE, 2011, v. 6, n. 9, p. 1, doi. 10.1371/journal.pone.0024433
- By:
- Publication type:
- Article
Whole-Genome Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissue Samples.
- Published in:
- PLoS ONE, 2009, v. 4, n. 12, p. 1, doi. 10.1371/journal.pone.0008162
- By:
- Publication type:
- Article
Anti-angiogenic Agents in Ovarian Cancer: Dawn of a New Era?
- Published in:
- Current Oncology Reports, 2011, v. 13, n. 6, p. 450, doi. 10.1007/s11912-011-0194-8
- By:
- Publication type:
- Article
Matulonis Provides Overview of Gynecologic Treatment Landscape Advances.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 3, p. 154
- By:
- Publication type:
- Article
New Advances in Ovarian Cancer.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 8, p. 721
- By:
- Publication type:
- Article
Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1–AKT–p53 Interactions.
- Published in:
- Cancers, 2021, v. 13, n. 9, p. 2195, doi. 10.3390/cancers13092195
- By:
- Publication type:
- Article
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.
- Published in:
- Cancers, 2020, v. 12, n. 8, p. 2054, doi. 10.3390/cancers12082054
- By:
- Publication type:
- Article
Immunotherapy for Ovarian Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2022, v. 20, n. 4, p. 240
- By:
- Publication type:
- Article
Management of Newly Diagnosed or Recurrent Ovarian Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2018, v. 16, n. 6, p. 426
- By:
- Publication type:
- Article
Acupuncture as Palliative Therapy for Physical Symptoms and Quality of Life for Advanced Cancer Patients.
- Published in:
- Integrative Cancer Therapies, 2010, v. 9, n. 2, p. 158, doi. 10.1177/1534735409360666
- By:
- Publication type:
- Article
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 4, p. 253, doi. 10.1177/1758834016687254
- By:
- Publication type:
- Article
A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors.
- Published in:
- 2001
- By:
- Publication type:
- journal article
CA125 Immune Complexes in Ovarian Cancer Patients with Low CA125 Concentrations.
- Published in:
- Clinical Chemistry, 2010, v. 56, n. 12, p. 1889, doi. 10.1373/clinchem.2010.153122
- By:
- Publication type:
- Article
Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalan.
- Published in:
- American Journal of Hematology, 1994, v. 45, n. 4, p. 283, doi. 10.1002/ajh.2830450403
- By:
- Publication type:
- Article
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
- Published in:
- British Journal of Cancer, 2018, v. 119, n. 9, p. 1075, doi. 10.1038/s41416-018-0271-y
- By:
- Publication type:
- Article
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
- Published in:
- British Journal of Cancer, 2016, v. 115, n. 11, p. 1313, doi. 10.1038/bjc.2016.348
- By:
- Publication type:
- Article
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Review: Erythropoiesis-stimulating agents increase mortality in patients with cancer.
- Published in:
- ACP Journal Club, 2009, v. 151, n. 3, p. 5
- By:
- Publication type:
- Article
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2015, v. 76, n. 2, p. 417, doi. 10.1007/s00280-015-2813-9
- By:
- Publication type:
- Article
Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Prediagnosis and postdiagnosis smoking and survival following diagnosis with ovarian cancer.
- Published in:
- International Journal of Cancer, 2020, v. 147, n. 3, p. 736, doi. 10.1002/ijc.32773
- By:
- Publication type:
- Article
Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer.
- Published in:
- International Journal of Cancer, 2020, v. 147, n. 2, p. 413, doi. 10.1002/ijc.32783
- By:
- Publication type:
- Article
Pre-diagnosis and post-diagnosis dietary patterns and survival in women with ovarian cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
PARP Inhibitor and PI3K Inhibitor Combo in Breast and Ovarian Cancers.
- Published in:
- Personalized Medicine in Oncology, 2015, v. 4, n. 3, p. 174
- By:
- Publication type:
- Article
Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer.
- Published in:
- Nature Communications, 2017, v. 8, n. 1, p. 1, doi. 10.1038/s41467-017-02390-7
- By:
- Publication type:
- Article
Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response.
- Published in:
- Nature Communications, 2017, v. 8, n. 1, p. 1, doi. 10.1038/s41467-017-00263-7
- By:
- Publication type:
- Article
Highlights in Ovarian Cancer From the 2017 American Society of Clinical Oncology Annual Meeting: Commentary.
- Published in:
- Clinical Advances in Hematology & Oncology, 2017, v. 15, p. 13
- By:
- Publication type:
- Article
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).
- Published in:
- 2016
- By:
- Publication type:
- journal article
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.
- Published in:
- 2016
- By:
- Publication type:
- journal article